Table 2.
Patient and baseline characteristics.
| Characteristics | Total patients (n = 58), mean ± SD/median (range)/n (%) |
|---|---|
| Age (years) | 55.2 ± 10.6 |
| Male sex | 49 (84.5) |
| ECOG PS | |
| 0 | 23 (39.7) |
| 1 | 35 (60.3) |
| Macrovascular invasion | |
| Yes | 21 (36.2) |
| No | 37 (63.8) |
| Extrahepatic disease | |
| Yes | 34 (58.6) |
| No | 24 (41.4) |
| Site of target lesion | |
| Liver | 50 (86.2) |
| Lung | 7 (12.1) |
| Lymph node | 16 (27.6) |
| Peritoneum | 8 (13.8) |
| Bone | 2 (3.4) |
| Ovary | 1 (1.7) |
| Adrenal gland | 1 (1.7) |
| Baseline α-fetoprotein ≥200 ng/ml | 28 (48.3) |
| Child–Pugh class | |
| A | 57 (98.3) |
| B | 1 (1.7) |
| BCLC stage | |
| B (intermediate) | 13 (22.4) |
| C (advanced) | 45 (77.6) |
| Liver cirrhosis (investigator assessed) | |
| Yes | 39 (67.2) |
| No | 19 (32.8) |
| Etiology of HCC: hepatitis B virus | |
| Yes | 56 (96.6) |
| No | 2 (3.4) |
| No. of target lesions | |
| 1 | 19 (32.7) |
| 2 | 25 (43.1) |
| 3 | 11 (19.0) |
| 5 | 3 (5.2) |
| First-line therapy | 58 (100.0) |
| Duration of combined treatment (months) | 5.8 (2.4–11.4) |
| Time between initiation and first evaluation (months) | 1.3 (1.2–1.5) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status; BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.